Send us a text

Surfing NASH returns to its regular program with a fresh episode and some fascinating and progressive ideas around non-invasive testing. Mazen Noureddin joins co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to discuss serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). In late July, Mazen co-authored a paper on the subject which was published in Hepatology.

This conversation begins with Louise’s focus on pediatric cohorts and whether MASEF can be applied to younger populations. Mazen states that while it has yet to be applied in this way, he would be very interested to learn more and invites anyone interested to reach out. From here Roger steers the discussion towards the future MASEF and what Mazen would like to have happen next in terms of its progress. Mazen notes the surprisingly fast commercial uptake of metabolomics tests and talks about how it might soon roll out in the US. Ultimately, he hopes if proven to be a good test that this will help replace biopsy. 

The remainder of the conversation considers a question from Louise around how MASEF could be adapted for the newly classified Met-ALD (those with MASLD who consume greater amounts of alcohol per week).

If you have questions or comments around MASEF, metabolomics or any other ideas considered in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected]. The Surfing the NASH Tsunami will be back next week with more original content.

Stay Safe and Surf On!